Vantia Therapeutics Ltd, a venture capital-financed pharmaceutical company, has appointed Andrew Crockett as vice president for business development.
Previously, he held the same position at ZARS Pharma, a US-based specialty pharmaceutical company. During his career, Mr Crockett has served as an advisor to groups investing in the medical device and pharmaceutical industries and to US-based start-up companies. Mr Crockett studied at Harvard Business School and holds a master of business administration degree from the Wharton School at the University of Pennsylvania with a major in finance.
Based in Southampton, UK, Vantia is developing small molecule drugs for nocturia and dysmenorrhoea.
Copyright 2009 Evernow Publishing Ltd